Management of Lamotrigine in UGT1A4 Ultra Rapid Metabolizers

Clinical Management Strategies

• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, recommends monitoring of lamotrigine serum concentrations more frequently when initiating therapy or adjusting doses to ensure therapeutic levels are achieved in patients identified as UGT1A4 ultra rapid metabolizers 1
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, suggests titrating lamotrigine more aggressively while still following safety protocols to prevent adverse effects in UGT1A4 ultra rapid metabolizers 1
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, advises avoiding co-administration with drugs that further induce UGT enzymes as this could exacerbate the rapid metabolism of lamotrigine in UGT1A4 ultra rapid metabolizers 1
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, recommends considering the impact of pregnancy on lamotrigine clearance, which may require additional dose adjustments in UGT1A4 ultra rapid metabolizers 1
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, suggests regularly assessing renal and hepatic function as they can impact overall drug clearance in UGT1A4 ultra rapid metabolizers 1
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, warns against overlooking the potential for increased side effects during dose titration, even though higher doses may ultimately be needed in UGT1A4 ultra rapid metabolizers 1
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, recommends considering the impact of concomitant medications on lamotrigine metabolism, particularly those affecting UGT enzymes in UGT1A4 ultra rapid metabolizers 1